Fig 2 - by Yajie Hu (550783)

Genome-Wide Association Study with Targeted and Non-targeted NMR Metabolomics Identifies 15 Novel Loci of Urinary Human Metabolic Individuality by Johannes Raffler (793347)

“…In contrast, for the <i>SLC5A11</i> locus, we found increased levels of <i>myo</i>-inositol in urine whereas mGWAS in blood reported decreased levels for the same genetic variant. …”

Increased serum EN-RAGE and decreased serum sRAGE are associated with COPD disease severity. by Debra A. Cockayne (158612)

Inhibition of ADAM10 or γ-secretase decreases the abundance of endogenous Fe65 in the nuclear fraction. by Niina A. Koistinen (3850717)

As the number of infections <i>I</i> in a given county increases, the variance in exponential growth rate, Var(Δ<i>I</i>/<i>I</i>), decreases as . by Calvin Pozderac (10451496)

Mutations in p38 MAP kinase components and the mucolipin ortholog CUP-5 suppress the decrease in abundance of EVA-1 in <i>madd-3</i> mutants. by Serena A. D’Souza (2635801)

Mutations in p38 MAP kinase components and the mucolipin ortholog CUP-5 suppress the decrease in abundance of RAB-7 in <i>madd-3</i> mutants. by Serena A. D’Souza (2635801)

Pharmacological inhibition of Hsp90 with GdA decreased apoptosis and caspase activity of <i>C. albicans.</i> by BaoDi Dai (307154)

Expression of Egln3 decreases tumor aggression, increases survival and normalizes glioma vascular architecture. by Vicki A. Sciorra (312082)

Image_1_Prediabetes: Adherence to Nutrition Visits Decreases HbA1c in Children and Adolescents.tiff by Sadichchha Parajuli (11716967)

Decreased Serum Level of miR-146a as Sign of Chronic Inflammation in Type 2 Diabetic Patients by Lucy Baldeón R. (674016)

“…We correlated outcomes to clinical parameters, including BMI, HbA1c and lipid state.</p><p>Results</p><p>The Ecuadorian non-diabetic controls appeared as overweight (BMI>25: patients 85%, controls 82.5%) and as dyslipidemic (hypercholesterolemia: patients 60.7%, controls 67.5%) as the patients.…”

Decreased striatal Drd1 mRNA expression during the early, but not late, phase of motor skill learning. by Yu Qian (153240)

EMS decreases female fecundity and <i>Wolbachia</i> titre in the next generation in a dose-dependent manner. by Elves H. Duarte (10994504)

TNP increases while Gd³⁺ decreases BASIC activity in a dose-dependent manner. by Axel Schmidt (652713)

Amplitude for A/L = 0.29. by Muhammad Hammad Bucha (21736111)

“…The smoothest cylinder (K_s/D = ) produced the highest power (52.325 µW), while the roughest (K_s/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”

Amplitude for A/L = 0.338. by Muhammad Hammad Bucha (21736111)

“…The smoothest cylinder (K_s/D = ) produced the highest power (52.325 µW), while the roughest (K_s/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”

Amplitude for A/L = 0.02. by Muhammad Hammad Bucha (21736111)

“…The smoothest cylinder (K_s/D = ) produced the highest power (52.325 µW), while the roughest (K_s/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”

Amplitude for A/L = 0.03. by Muhammad Hammad Bucha (21736111)

“…The smoothest cylinder (K_s/D = ) produced the highest power (52.325 µW), while the roughest (K_s/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”

Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC₅₀ concentration of fenretinide during different time points (24–48–72 hours). …”

Image_4_v1_Systemic Immune Modulation Alters Local Bone Regeneration in a Delayed Treatment Composite Model of Non-Union Extremity Trauma.jpeg by Casey E. Vantucci (10528263)

“…This overall increase correlated with a decrease in bone volume (P = 0.057) at 6 weeks post-treatment and a significant decrease in mechanical strength at 12 weeks post-treatment compared to untreated rats. …”